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homology. The last of the human sequences differed at 
2 positions owing to mixed bases. The chromatogram 
showed equal intensities at both positions C and T (Figure, 
http://wwwnc.cdc.gov/EID/article/22/11/16-1171-F1.
htm). This finding indicates that quasispecies might be 
present. These positions in the human sequence coincided 
perfectly with 2 of the 3 positions found to vary in the 
sequence obtained from oyster sample D. All 3 base varia-
tions were a replacement of a C with a T (Figure), which 
further supports the presence of quasispecies. However, 
in this setup, it was not possible to prove the origin of 
these closely related species. Whole-genome sequenc-
ing using next-generation sequencing would be a way to 
prove the simultaneous presence of all quasispecies in rel-
evant samples.
Since the emerging of GII.P17-GII.17 in Asia, spo-
radic cases have been reported worldwide (3,9). In this 
study, we established a direct molecular link between a 
common food source and a series of acute gastroenteri-
tis outbreaks. Even though these represent European out-
breaks, our results show that oysters act as vehicles for the 
rapid spread of emerging noroviruses to distant geograph-
ic areas. Furthermore, we document that quasispecies of 
GII.P17-GII.17 might occur simultaneously in a host. 
This finding should be considered in future molecular- 
epidemiologic outbreak investigations.
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To the Editor: Since chikungunya virus (CHIKV) 
was first isolated in 1952 (in Tanzania), outbreaks have oc-
curred every 7–20 years in countries in Africa and Asia, 
and since 2013, it has been identified in the Americas (1,2). 
However, no cases have been reported from the Horn of 
Africa (3,4). We confirmed CHIKV infection acquired in 
2016 by 2 travelers to Somalia who returned to Italy.
In June 2016, a Somali woman (patient 1) was referred 
to the Infectious and Tropical Diseases Unit, Careggi Uni-
versity Hospital, in Florence, Italy, because of severe diffuse 
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bilateral arthralgia and edema in hands, wrists, ankles, and 
feet. Five days earlier, she had returned to Italy from Moga-
dishu, Somalia, where she had spent 45 days visiting rela-
tives. The woman had been living in Italy since the 1990s 
and returned to Somalia each year for ≈2 months; she denied 
travel to other countries. She reported that symptoms started 
abruptly in May, 17 days after arriving in Somalia (28 days 
before returning to Italy). At symptom onset, arthralgia was 
associated with fever and skin rash, which lasted a few days.
In early July 2016, another Somali woman (patient 2) 
with bilateral arthralgia in her hands, wrists, ankles, and 
feet associated with foot edema sought medical care at the 
same hospital 7 days after returning from a 65-day trip to 
Mogadishu, where she visited relatives. The woman had 
been living in Italy ≈20 years; the only other travel she 
reported was to Kenya in 2012. Her symptoms started in 
June, 20 days after arriving in Somalia (45 days before re-
turning to Italy). At symptom onset, she also had skin rash 
and fever, which lasted a few days.
Both patients reported that, during the same period, 
some of their relatives in Mogadishu had similar symptoms 
and were clinically diagnosed as having chikungunya fever 
by local doctors. Both also reported that, during the same 
period, other cases had been reported in Mogadishu by 
mass and social media and, thus, the local population was 
aware of the disease.
Serum samples for patients 1 and 2 were positive for 
CHIKV antibodies (Table). Both patients were treated with 
nonsteroidal antiinflammatory drugs and corticosteroids 
and are receiving follow-up.
According to the US Centers for Disease Control and 
Prevention, as of April 22, 2016, CHIKV had not been 
reported from Somalia (4), and no evidence exists for 
CHIKV circulation in that area of the Horn of Africa (3). 
In addition, on August 3, 2016, we performed a literature 
search in PubMed, Embase, and ProMED-mail, and found 
no reports of CHIKV in Somalia. Poorly documented pre-
liminary data on the presence of CHIKV in Somalia were 
recently reported in 2 documents by the United Nations 
Office for the Coordination of Humanitarian Affairs. One 
document, dated June 7, 2016, stated “There are reports of 
an outbreak of the deadly Chikungunya virus in Banadir 
Region. According to WHO [the World Health Organiza-
tion], 3 of 5 blood samples have tested positive” (refer-
ence 1 in online Technical Appendix, http://wwwnc.cdc.
gov/EID/article/22/11/16-1225-Techapp1.pdf). The second 
document, dated June 30, 2016, stated that “some 11 sus-
pected cases of Chikungunya were confirmed... in Moga-
dishu” (reference 2 in online Technical Appendix). Several 
reports in the online press and social media have reported 
the current circulation of CHIKV in Somalia, including 2 
Twitter posts (tweets) by the Ministry of Health of Kenya 
(references 3–7 in online Technical Appendix). A Somali 
doctor living in Italy obtained confirmation of CHIKV cir-
culation in Somalia by contacting colleagues at the Min-
istry of Health in Mogadishu (Omar Abdulcadir, Careggi 
University Hospital, pers. comm., 2016 Jul 19).
Direct and indirect evidence exists for the presence of 
competent CHIKV vectors (e.g., Aedes aegypti mosqui-
toes) in Somalia. Entomologic studies conducted in 1942 
and 1969 confirmed the presence of A. aegypti mosquitoes 
in several cities along Somalia’s coast, including Moga-
dishu (5). Other arboviruses in which Aedes mosquitoes 
play a role as reservoir (Rift valley fever [RVF]) and vector 





Table. Results of chikungunya virus testing for 2 persons who returned to Italy after traveling to Mogadishu, Somalia, 2016* 
Laboratory test performed Place where test was performed 
Results 
Patient 1† Patient 2‡ 
OnSite Chikungunya IgM Combo Rapid Test-
Cassette (CTK Biotech, San Diego CA, USA)§ 
Careggi University Hospital Positive Negative 
Chikungunya virus IFA IgG (Euroimmun AG, 
Luebeck, Germany)¶ 
Careggi University Hospital Titer >1:100# Titer >1:100# 
Chikungunya virus IFA IgM (Euroimmun)** Careggi University Hospital Positive Positive 
Anti-CHIKV IgM ELISA (Euroimmun)†† ISS, National Reference Laboratory 
for Arboviruses 
Index 7.9‡‡ Index 3.4‡‡ 
PRNT for Chikungunya virus ISS, National Reference Laboratory 
for Arboviruses 
PRNT80 >1:10§§ PRNT80 >1:10§§ 
*Testing was conducted on samples taken the day patients 1 and 2 sought care at the Infectious and Tropical Diseases Outpatient Unit at Careggi 
University Hospital in Florence, Italy. IFA, immunofluorescence assay; ISS, National Institute of Health in Rome, Italy; PRNT, plaque reduction 
neutralization test; PRNT80, 80% PRNT. 
†Samples were obtained 33 d after symptom onset.  
‡Samples were obtained 52 d after symptom onset.  
§Sensitivity/specificity 90.3%/100% according to information reported in the kit data sheet (reference 10 in online Technical Appendix, 
http://wwwnc.cdc.gov/EID/article/22/11/16-1225-Techapp1.pdf) and 30%/73% according to an independent evaluation (reference 11 in online Technical 
Appendix). 
¶Sensitivity/specificity 100%/96% according to information reported in the kit data sheet (reference 12 in online Technical Appendix).  
#Cut-off for positivity >1:10.  
**Sensitivity/specificity 95%/96% according to information reported in the kit data sheet (reference 12 in online Technical Appendix )).  
††Sensitivity/specificity 98.1%/98.9% according to information reported in the kit data sheet (reference 13 in online Technical Appendix) and 85%/82% 
according to an independent evaluation (reference 11 in online Technical Appendix). 
‡‡Cut-off for positivity >1.1.  
§§PRNT80 titers >1:10 are considered positive. 
 
(dengue and possibly RVF) have been reported in recent 
years in Somalia: RVF outbreaks occurred during 1997–
1998 and 2006–2007 (6,7), and a dengue outbreak occurred 
during 1992–1993 (8).
The current outbreak in Somalia could have been trig-
gered by several factors, including circulation of CHIKV 
in neighboring Kenya (references 8,9 in online Technical 
Appendix) and heavy rains that led to flooding in southern 
and central Somalia beginning in January 2016 (reference 
1 in online Technical Appendix). CHIKV has the potential 
to provoke explosive outbreaks in naive populations (9), so 
the current outbreak may greatly affect the economy and 
public health in Somalia.
Systematic studies to understand the magnitude of the 
ongoing epidemic are needed. In the meantime, local pub-
lic health stakeholders in Somalia and healthcare work-
ers worldwide caring for travelers returning from Somalia 
should be aware that CHIKV is circulating in the country. 
This report confirms the importance of travel medicine 
services in performing early diagnosis of imported arbo-
viral diseases, not only to thwart secondary transmission 
during periods of competent vector activity but also to 
help to detect or confirm virus circulation in previously 
unaffected countries.
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To the Editor: In their recent letter (1), Broderick 
et al. provided useful information about the remarkable 
declines in incidence of meningococcal disease among 
active-duty US military personnel since the early 1970s, 
when meningococcal vaccination began within that pop-
ulation. The authors reported that the incidence of me-
ningococcal disease from vaccine-covered serogroups 
was 0.183 cases/100,000 persons during 2006–2013 
among persons vaccinated with quadrivalent conjugate 
meningococcal vaccine (MCV-4), compared with 0.307 
cases/100,000 persons during 2000–2013 among persons 
vaccinated with quadrivalent polysaccharide meningo-
coccal vaccine (MPSV-4). They stated that, because these 
rates did not differ significantly, case rates were similar 
in personnel vaccinated with MCV-4 and MPSV-4. Al-
though statistically correct, this comment might mislead 
the unwary reader.
The absence of a significant difference does not nec-
essarily mean that the 2 vaccines have similar effective-
ness. The incidence rate of meningococcal disease was 
68% higher ([0.307–0.183] × 100/0.183) during the pe-
riod of MPSV-4 use than during the period of MCV-4 use. 
If the same findings arose in a study of sufficient size to 
achieve statistical significance, this difference would be 
considered of substantial clinical importance. A happy 
consequence of the long-term temporal trends in menin-
gococcal incidence and the success of these vaccines is 
that the incidence of meningococcal disease is now suf-
ficiently reduced that even the very large active-duty 
population is too small to provide the statistical power to 
declare these 2 different incidence rates as being statisti-
cally different.
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